Cite
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group
MLA
Gilles Freyer, et al. “Author Correction: Bevacizumab, Olaparib, and Durvalumab in Patients with Relapsed Ovarian Cancer: A Phase II Clinical Trial from the GINECO Group.” Nature Communications, vol. 15, no. 1, June 2024, p. 1. EBSCOhost, https://doi.org/10.1038/s41467-024-48915-9.
APA
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, Cyril Abdeddaim, Alexandra Leary, Coraline Dubot-Poitelon, Michel Fabbro, Laurence Gladieff, & Michele Lamuraglia. (2024). Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group. Nature Communications, 15(1), 1. https://doi.org/10.1038/s41467-024-48915-9
Chicago
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques, Jonathan Lopez, Frédéric Selle, et al. 2024. “Author Correction: Bevacizumab, Olaparib, and Durvalumab in Patients with Relapsed Ovarian Cancer: A Phase II Clinical Trial from the GINECO Group.” Nature Communications 15 (1): 1. doi:10.1038/s41467-024-48915-9.